Special Issue

Magnetic Resonance in Cancer Research

Message from the Guest Editors

Since Rabi's first experiment on nuclear magnetic resonance (NMR) in 1938, magnetic resonance has become an indispensable medical imaging modality in cancer diagnosis and treatment monitoring. NMR-based metabolomics is now employed for tumor metabolic profiling to evaluate patients' response to cancer treatment. NMR is also a powerful tool in structural biology. The structural characterization of protein interactions with small molecules has led to novel drug designs. In this Special Issue, original research articles and reviews are welcome. Research areas may include, but are not limited to, the following: (a) clinical MRI of cancer and machine learning; (b) diffusion-weighted MRI (DWI) in cancer treatment assessment; (c) fast proton MRSI in cancer biomarker detection; (d) MRI evaluation of cardiotoxicity of cancer therapy; (e) PET/MRI of cancer; (f) MR characterization of tumor oxygenation; (g) molecular imaging of cancer; (h) hyperpolarization C-13 MRS in cancer metabolic imaging; (i) deuterium MRS in cancer biomarker imaging; and (j) F-19 MRI in cancer drug metabolism and cell tracking, etc. We look forward to receiving your contributions.

Guest Editors

Dr. Qiuhong He

School of Health Sciences, Purdue University, West Lafayette, IN 47907, USA

Dr. Marie-France Vidaver

Department of Radiology and Radiological Science, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA

Deadline for manuscript submissions

closed (15 April 2025)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/183445

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)